Indeed, PRMT5 depletion/inhibition sensitizes tumor cells to drugs inducing the DDR, exemplified by cytarabine (MLL-rearranged leukemia, [132]), PARP inhibitors (AML, [69]) and camptothecin, a topoisomerase inhibitor [92]. This evidence concerns the gene KMT2A and acute myeloid leukemia.